Lupus & antiphospholipid syndrome
Relationship of systemic type I interferon activity with clinical phenotypes, disease activity, and damage accrual in systemic lupus erythematosus in treatment-naive patients: a retrospective longitudinal analysis
Authors' conclusion
Serum IFN activity is characteristically high and is linked to fever, hematologic disorders, and mucocutaneous manifestations in treatment-naive SLE patients. Serum IFN activity at baseline correlates with disease activity and decreases in parallel with a decrease in disease activity after induction and maintenance therapy.
Study context
- Population
- Treatment-naive systemic lupus erythematosus (SLE) patients before and after induction and maintenance therapy
- Participants
- 40 / 59 / 33
- Exposure
- Treatment-naive SLE vs other treatment-naive rheumatic disease patients and healthy individuals
- SLEn = 40
- Other rheumatic diseasen = 59reference
- Healthy individualsn = 33
- Outcome
- Relationship of serum IFN activity (WISH bioassay, IFN activity score) with clinical phenotypes (EULAR/ACR-2019 domains), disease activity and damage accrual
Methodological detailsWISH bioassay
- WISH bioassay
Main finding
As reported in the abstract
Serum IFN activity score · baseline
SLE
97.6
Other rheumatic disease
0.0
P < 0.001
- Baseline interferon (IFN) activity correlated with SLEDAI-2K and decreased with SLEDAI-2K after induction and maintenance therapy
- R2 = 0.112, p = 0.034
Observational data: associations, not effects.
Further findings
| Outcome | SDI ≥ 1 | SDI = 0 | P value |
|---|---|---|---|
| Baseline serum IFN activity by organ damage (SDI ≥ 1 vs SDI = 0) | 150.0 | 57.3 | P = 0.018 |
- Baseline serum IFN activity by organ damage (SDI ≥ 1 vs SDI = 0): multivariate analysis did not detect independent significance (p = 0.132)
Original publication
Relationship of systemic type I interferon activity with clinical phenotypes, disease activity, and damage accrual in systemic lupus erythematosus in treatment-naive patients: a retrospective longitudinal analysis. Arthritis Res Ther. Published 17 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →